Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe

European Journal of Internal Medicine

Volumn 37, Issue , 2017, Pages 25-32

  Belmatoug, Nadia ^a   Di Rocco, Maja ^b   Fraga, Cristina ^c   Giraldo, Pilar ^d   Hughes, Derralynn ^e   Lukina, Elena ^f   Maison Blanche, Pierre ^g   Merkel, Martin ^h   Niederau, Claus ⁱ   Plӧckinger, Ursula ^j   Richter, Johan ^k   Stulnig, Thomas M ^l   vom Dahl, Stephan ^m   Cox, Timothy M ⁿ  

^a BEAUJON HOSPITAL   (France)

^b G GASLINI INSTITUTE   (Italy)

^c HDES Hospital   (Portugal)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^g BICHAT HOSPITAL   (France)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k LUND UNIVERSITY HOSPITAL   (Sweden)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Drug interactions; Drug metabolism; Eliglustat; Enzyme replacement augmentation therapy; Substrate reduction therapy; Type 1 Gaucher disease

Indexed keywords

CYTOCHROME P450 2D6; ELIGLUSTAT; MIGLUSTAT; CERAMIDE GLUCOSYLTRANSFERASE; ENZYME INHIBITOR; GLUCOSYLTRANSFERASE; PYRROLIDINE DERIVATIVE;

ADULT; CLINICAL OUTCOME; DRUG INTERACTION; DRUG METABOLISM; ELECTROCARDIOGRAM; ENZYME REPLACEMENT; EUROPE; FEMALE FERTILITY; GAUCHER DISEASE; GENOTYPE; HUMAN; KIDNEY FUNCTION; LACTATION; LIVER FUNCTION; LONG TERM CARE; MALE FERTILITY; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGERY; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; METABOLISM; PHENOTYPE; PRACTICE GUIDELINE;

CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; ENZYME REPLACEMENT THERAPY; EUROPE; GAUCHER DISEASE; GLUCOSYLTRANSFERASES; HUMANS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PYRROLIDINES;

EID: 84994285410     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2016.07.011     Document Type: Review

References (47)

1. [1] CERDELGA™, Summary of product characteristics. 2014, Genzyme Corporation, a Sanofi Company, Waterford, Ireland.
2. [2] Charrow, J., Esplin, J.A., Gribble, T.J., Kaplan, P., Kolodny, E.H., Pastores, G.M., et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158 (1998), 1754–1760.
3. [3] Pastores, G.M., Weinreb, N.J., Aerts, H., Andria, G., Cox, T.M., Giralt, M., et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41 (2004), 4–14.
4. [4] Weinreb, N.J., Aggio, M.C., Andersson, H.C., Andria, G., Charrow, J., Clarke, J.T., et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41 (2004), 15–22.
5. [5] Mistry, P.K., Cappellini, M.D., Lukina, E., Ozsan, H., Mach Pascual, S., Rosenbaum, H., et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol 86 (2011), 110–115.
6. [6] Balwani, M., Burrow, T.A., Charrow, J., Goker-Alpan, O., Kaplan, P., Kishnani, P.S., et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab, 2015.
7. [7] Grabowski, G.A., Andria, G., Baldellou, A., Campbell, P.E., Charrow, J., Cohen, I.J., et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 163 (2004), 58–66.
8. [8] Grabowski, G.A., Petsko, G.A., Kolodny, E.H., Gaucher disease. Valle, D., Beaudet, A.L., Vogelstein, B., Kinzler, K.W., Antonarakis, S.E., Ballabio, A., et al., (eds.) OMMBID: the online metabolic and molecular bases of inherited disease, 2013, McGraw-Hill, New York, NY [Available at: http://ommbid.mhmedical.com/content.aspx?bookid=474&Sectionid=45374148].
9. [9] Mistry, P.K., Deegan, P., Vellodi, A., Cole, J.A., Yeh, M., Weinreb, N.J., Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 147 (2009), 561–570.
10. [10] Mistry, P.K., Weinreb, N.J., Kaplan, P., Cole, J.A., Gwosdow, A.R., Hangartner, T., Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 46 (2011), 66–72.
11. [11] Goker-Alpan, O., Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab 104 (2011), 438–447.
12. [12] Mistry, P.K., Sirrs, S., Chan, A., Pritzker, M.R., Duffy, T.P., Grace, M.E., et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77 (2002), 91–98.
13. [13] Terk, M.R., Dardashti, S., Liebman, H.A., Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol 29 (2000), 563–571.
14. [14] Mistry, P.K., Weinthal, J.A., Weinreb, N.J., Disease state awareness in Gaucher disease: a Q&a expert roundtable discussion. Clin Adv Hematol Oncol 10 (2012), 1–16.
15. [15] Pastores, G.M., Hughes, D.A., Gaucher disease. Pagon, R.A., Adam, M.P., Ardinger, H.H., (eds.) GeneReviews, 2013, University of Washington, Seattle, Seattle, WA.
16. [16] Weinreb, N.J., Charrow, J., Andersson, H.C., Kaplan, P., Kolodny, E.H., Mistry, P., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med 113 (2002), 112–119.
17. [17] de Fost, M., Hollak, C.E., Groener, J.E., Aerts, J.M., Maas, M., Poll, L.W., et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108 (2006), 830–835.
18. [18] Weinreb, N.J., Barranger, J., Packman, S., Prakash-Cheng, A., Rosenbloom, B., Sims, K., et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71 (2007), 576–588.
19. [19] Cox, T.M., Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 11 (2010), 1169–1181.
20. [20] McEachern, K.A., Fung, J., Komarnitsky, S., Siegel, C.S., Chuang, W.L., Hutto, E., et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91 (2007), 259–267.
21. [21] Shayman, J.A., Eliglustat tartrate: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35 (2010), 613–620.
22. [22] Zavesca (miglustat), Summary of product characteristics. 2013, Actelion Pharmaceuticals UK Ltd.
23. [23] Brand, M., Muller, A., Alsop, J., van Schaik, I.N., Bembi, B., Hughes, D., Results from a 9-year intensive safety surveillance scheme in miglustat (Zavesca(R))-treated patients. Pharmacoepidemiol Drug Saf 24 (2015), 329–333.
24. [24] Cox, T.M., Aerts, J.M., Andria, G., Beck, M., Belmatoug, N., Bembi, B., et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26 (2003), 513–526.
25. [25] Schiffmann, R., Fitzgibbon, E.J., Harris, C., DeVile, C., Davies, E.H., Abel, L., et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 64 (2008), 514–522.
26. [26] Lau, H., Ibrahim, J., Peterschmitt, M.J., Ross, L., Tremor and peripheral neuropathy are infrequent and non-serious events in Gaucher type 1 patients treated with eliglustat [abstract]. Mol Genet Metab 114 (2015), S69–S70.
27. [27] Lukina, E., Watman, N., Arreguin, E.A., Banikazemi, M., Dragosky, M., Iastrebner, M., et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116 (2010), 893–899.
28. [28] Lukina, E., Watman, N., Arreguin, E.A., Dragosky, M., Iastrebner, M., Rosenbaum, H., et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116 (2010), 4095–4098.
29. [29] Mistry, P.K., Lukina, E., Ben Turkia, H., Amato, D., Baris, H., Dasouki, M., et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA 313 (2015), 695–706.
30. [30] Mistry, P.K., Amato, D.J., Dasoukic, M., Packman, S., Pastores, G.M., Assouline, S., et al. ENGAGE: a phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with Gaucher disease type 1: results after 18 months [abstract]. Mol Genet Metab 114 (2015), S81–S82.
31. [31] Lukina, E., Watman, N., Dragosky, M., Pastores, G.M., Arreguin, E.A., Rosenbaum, H., et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 53 (2014), 274–276.
32. [32] Cox, T.M., Drelichman, G., Cravo, R., Balwani, M., Burrow, T.A., Martins, A.M., et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 385 (2015), 2355–2362.
33. [33] Cox, T.M., Drelichman, G., Cravo, R., Balwani, M., Burrow, T.A., Martins, A.M., et al. ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results [abstract]. Mol Genet Metab 114 (2015), S33–S34.
34. [34] Kamath, R.S., Lukina, E., Watman, N., Dragosky, M., Pastores, G.M., Arreguin, E.A., et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol 43 (2014), 1353–1360.
35. [35] Hidaka, M., Okumura, M., Fujita, K., Ogikubo, T., Yamasaki, K., Iwakiri, T., et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 33 (2005), 644–648.
36. [36] Hosoi, S., Shimizu, E., Arimori, K., Okumura, M., Hidaka, M., Yamada, M., et al. Analysis of CYP3A inhibitory components of star fruit (Averrhoa carambola L.) using liquid chromatography-mass spectrometry. J Nat Med 62 (2008), 345–348.
37. [37] Malhotra, S., Bailey, D.G., Paine, M.F., Watkins, P.B., Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 69 (2001), 14–23.
38. [38] Foti, R.S., Wahlstrom, J.L., Wienkers, L.C., The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Dispos 35 (2007), 185–188.
39. [39] Kim, S., O, H., Kim, J.A., Lee, S.H., Lee, S., In vitro inhibitory effect of licoricidin on human cytochrome P450s. Mass Spectrosc Lett 5 (2014), 84–88.
40. [40] Li, G., Huang, K., Nikolic, D., van Breemen, R.B., High-throughput cytochrome P450 cocktail inhibition assay for assessing drug–drug and drug-botanical interactions. Drug Metab Dispos 43 (2015), 1670–1678.
41. [41] Elstein, D., Hughes, D., Goker-Alpan, O., Stivel, M., Baris, H.N., Cohen, I.J., et al. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res 40 (2014), 968–975.
42. [42] Granovsky-Grisaru, S., Belmatoug, N., vom Dahl, S., Mengel, E., Morris, E., Zimran, A., The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 156 (2011), 3–8.
43. [43] Sekijima, Y., Ohashi, T., Ohira, S., Kosho, T., Fukushima, Y., Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clin Ther 32 (2010), 2048–2052.
44. [44] Zimran, A., Morris, E., Mengel, E., Kaplan, P., Belmatoug, N., Hughes, D.A., et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 43 (2009), 264–288.
45. [45] Ruskin, J.N., Ortemann-Renon, C., Ross, L., Mankoski, R., Puga, A.C., Peterschmitt, M.J., et al. Electrocardiographic evaluation of eliglustat: results of a thorough QT study and phase 2 and 3 clinical trials [asbtract]. European working group on Gaucher disease 11th meeting. Haifa, Israel, 2014.
46. [46] Ross, L., Peterschmitt, M.J., Puga, A.C., Cox, G.F., Marulkar, S., Angell, J., et al. Eliglustat adverse event data from a pooled analysis of four trials in Gaucher disease type 1 [abstract]. Mol Genet Metab, 111, 2014, S90.
47. [47] Rosenbaum, H., Hemorrhagic aspects of Gaucher disease. Rambam Maimonides Med J, 5, 2014, e0039.